HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 134 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2014. The put-call ratio across all filers is 1.16 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,920,047 | -6.5% | 50,263 | -11.7% | 0.00% | 0.0% |
Q2 2023 | $2,053,032 | -13.7% | 56,918 | -8.7% | 0.00% | -20.0% |
Q1 2023 | $2,380,154 | -34.4% | 62,324 | -2.3% | 0.01% | -37.5% |
Q4 2022 | $3,628,399 | +57.3% | 63,768 | +9.3% | 0.01% | +33.3% |
Q3 2022 | $2,307,000 | -3.3% | 58,337 | +7.6% | 0.01% | +20.0% |
Q2 2022 | $2,385,000 | +4.0% | 54,200 | -5.7% | 0.01% | +25.0% |
Q1 2022 | $2,293,000 | -4.0% | 57,488 | -3.2% | 0.00% | 0.0% |
Q4 2021 | $2,388,000 | -8.0% | 59,394 | -7.0% | 0.00% | -20.0% |
Q3 2021 | $2,597,000 | -19.7% | 63,848 | -10.4% | 0.01% | -16.7% |
Q2 2021 | $3,236,000 | +5.1% | 71,252 | -3.5% | 0.01% | +20.0% |
Q1 2021 | $3,078,000 | -4.4% | 73,833 | -2.1% | 0.01% | -16.7% |
Q4 2020 | $3,221,000 | +33.3% | 75,414 | -18.0% | 0.01% | +50.0% |
Q3 2020 | $2,417,000 | -13.5% | 91,956 | -11.8% | 0.00% | -20.0% |
Q2 2020 | $2,794,000 | +84.1% | 104,202 | +23.5% | 0.01% | +66.7% |
Q1 2020 | $1,518,000 | -27.5% | 84,366 | -28.6% | 0.00% | +50.0% |
Q4 2019 | $2,095,000 | -1.1% | 118,170 | -13.5% | 0.00% | 0.0% |
Q3 2019 | $2,118,000 | -9.8% | 136,579 | -0.1% | 0.00% | -33.3% |
Q2 2019 | $2,349,000 | +6.2% | 136,726 | -0.4% | 0.00% | +50.0% |
Q1 2019 | $2,211,000 | +10.8% | 137,343 | +0.7% | 0.00% | 0.0% |
Q4 2018 | $1,995,000 | -36.1% | 136,385 | -20.6% | 0.00% | -33.3% |
Q3 2018 | $3,121,000 | +7.7% | 171,773 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $2,898,000 | -13.9% | 171,773 | 0.0% | 0.00% | -25.0% |
Q1 2018 | $3,365,000 | +2.0% | 171,773 | +5.5% | 0.00% | +33.3% |
Q4 2017 | $3,299,000 | +66.2% | 162,825 | +42.5% | 0.00% | +50.0% |
Q3 2017 | $1,985,000 | +553.0% | 114,248 | +381.1% | 0.00% | – |
Q2 2017 | $304,000 | +50.5% | 23,748 | +52.8% | 0.00% | – |
Q1 2017 | $202,000 | +32.0% | 15,546 | 0.0% | 0.00% | – |
Q4 2016 | $153,000 | -18.6% | 15,546 | -0.5% | 0.00% | – |
Q3 2016 | $188,000 | +39.3% | 15,629 | 0.0% | 0.00% | – |
Q2 2016 | $135,000 | -44.9% | 15,629 | -39.7% | 0.00% | – |
Q1 2016 | $245,000 | -83.8% | 25,911 | -70.2% | 0.00% | -100.0% |
Q4 2015 | $1,509,000 | +16.8% | 87,059 | -9.5% | 0.00% | 0.0% |
Q3 2015 | $1,292,000 | -45.7% | 96,230 | -8.7% | 0.00% | -40.0% |
Q2 2015 | $2,381,000 | +397.1% | 105,442 | +213.8% | 0.01% | +400.0% |
Q1 2015 | $479,000 | +143.1% | 33,600 | +64.7% | 0.00% | – |
Q4 2014 | $197,000 | -55.4% | 20,400 | -58.0% | 0.00% | -100.0% |
Q3 2014 | $442,000 | -31.2% | 48,555 | -25.2% | 0.00% | -50.0% |
Q2 2014 | $642,000 | -55.2% | 64,955 | -42.4% | 0.00% | -50.0% |
Q1 2014 | $1,432,000 | -4.9% | 112,755 | +12.2% | 0.00% | 0.0% |
Q4 2013 | $1,506,000 | +569.3% | 100,455 | +392.4% | 0.00% | +300.0% |
Q3 2013 | $225,000 | +38.9% | 20,400 | 0.0% | 0.00% | 0.0% |
Q2 2013 | $162,000 | -7.4% | 20,400 | -21.7% | 0.00% | 0.0% |
Q4 2012 | $175,000 | – | 26,049 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |